Highlights
- •Parkinson disease (PD) leads to many noticeable motor and nonmotor symptoms.
- •Pharmacologic treatments for PD symptoms have been found to be especially helpful when combined with nonpharmacologic approaches.
- •Cannabidiol has been used for PD symptom management.
- •However, more human model randomized clinical trials are needed for cannabidiol use in PD.
Abstract
Parkinson disease (PD) is a progressive neurodegenerative disorder characterized by
the decrease in dopaminergic neurons in the brain leading to motor and nonmotor symptoms.
With the increased availability of cannabidiol in the United States and interest in
the PD community for PD-related symptom management in complementary to pharmacologic
treatment, this review provides nurse practitioners with useful information on existing
studies and regulatory considerations on the implication of cannabidiol in PD.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal for Nurse PractitionersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Parkinson’s disease: clinical features and diagnosis.J Neurol Neurosurg Psychiatry. 2008; 79: 368-376
- Non-Movement Symptoms.https://www.parkinson.org/Understanding-Parkinsons/Non-Movement-SymptomsDate accessed: January 16, 2022
- Parkinson’s disease in adults: diagnosis and management. NICE guideline NG71.July 2017https://www.nice.org.uk/guidance/ng71/evidence/full-guideline-pdf-4538466253Date accessed: January 16, 2022
- Lewy body dementias: dementia with Lewy bodies and Parkinson disease dementia.Continuum. 2016; 22: 435-463https://doi.org/10.1212/CON.0000000000000309
- What is Parkinson’s? Causes.https://www.parkinson.org/Understanding-Parkinsons/CausesDate accessed: November 11, 2021
- Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?.Eur Arch Psychiatry Clin Neurosci. 2019; 269: 121-133https://doi.org/10.1007/s00406-019-00982-6
- Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a Medicare Part D population.Value Health. 2014; 17: 196-204https://doi.org/10.1016/j.jva1.2013.12.003
- Clinical problems in the hospitalized Parkinson’s disease patient: systematic review.Mov Disord. 2011; 26: 197-208
- Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review.Mov Disord. 2019; 34: 180-198https://doi.org/10.1002/mds.27602
- Nichtmedikamentöse Therapieverfahren beim Morbus Parkinson [Nonpharmacological treatment procedures for Parkinson’s disease].Nervenarzt. 2017; 88: 383-390https://doi.org/10.1007/s00115-017-0298-y
- Diagnosis and treatment of Parkinson disease: a review.JAMA. 2020; 323: 548-560https://doi.org/10.1001/jama.2019.22360
- Cannabis: are there any benefits?.Intern Med J. 2020; 50: 1326-1332https://doi.org/10.1111/imj.15052
- Clinicians’ guide to cannabidiol and hemp oils.Mayo Clin Proc. 2019; 94: 1840-1851https://doi.org/10.1016/j.mayocp.2019.01.003
- 14% of Americans Say They Use CBD Products.Gallup. August 7, 2019;https://news.gallup.com/poll/263147/americans-say-cbd-products.aspxDate accessed: December 1, 2021
- Biological bases for a possible effect of cannabidiol in Parkinson’s disease.Braz J Psychiatry. 2020; 42: 218-224https://doi.org/10.1590/1516-4446-2019-0460
- Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial.J Psychopharmacol. 2014; 28: 1088-1098https://doi.org/10.1177/0269881114550355
- Safety and tolerability of cannabidiol in Parkinson disease: an open label, dose-escalation study.Cannabis Cannabinoid Res. 2020; 5: 326-336https://doi.org/10.1089/can.2019.0068
- Cannabis and its derivatives for the use of motor symptoms in Parkinson’s disease: a systematic review and meta-analysis.Ther Adv Neurol Disord. 2021; 1417562864211018561https://doi.org/10.1177/17562864211018561
- Epidiolex (cannabidiol).https://www.epidiolex.com/sites/default/files/pdfs/1021/EPX-03633-1021_EPIDIOLEX_(cannabidiol)_USPI.pdfDate accessed: January 16, 2022
- Neuroprotective and symptomatic effects of cannabidiol in an animal model of Parkinson’s disease.Int J Mol Sci. 2021; 22: 8920https://doi.org/10.3390/ijms22168920
- Parkinson’s Foundation Consensus Statement on the Use of Medical Cannabis for Parkinson’s Disease.(Published 2020)https://www.parkinson.org/sites/default/files/Medical%20Cannabis%20Statement_FINALv2_2.pdfDate accessed: December 1, 2021
- Cannabidiol products: review of the regulatory and clinical considerations.J Nurse Pract. 2020; 16: 747-755https://doi.org/10.1016/j.nurpra.2020.07.022
- Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy.J Alzheimers Dis. 2013; 35: 525-539
- Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.Clin Neuropharmacol. 2014; 37: 41-44
- Drug interaction report.https://www.drugs.com/interactions-check.php?drug_list=2758-0,515-250Date accessed: February 24, 2022
- What are the benefits of CBD—and is it safe to use?.(Published December 18, 2020)https://www.mayoclinic.org/healthy-lifestyle/consumer-health/expert-answers/is-cbd-safe-and-effective/faq-20446700Date accessed: February 24, 2022
Biography
Helen Kim, BSN, RN, University of Washington Medical Center, Seattle.
Biography
Sharon Zhang, BSN, RN, Seattle University College of Nursing, Seattle, WA.
Biography
Mo-Kyung Sin, PhD, RN, is an associate professor at Seattle University College of Nursing, Seattle, WA, and can be contacted at si[email protected]
Article info
Publication history
Published online: May 04, 2022
Footnotes
Funding: This project was supported by a Seattle University College of Nursing Seed Grant.
In compliance with standard ethical guidelines, the authors report no relationships with business or industry that would pose a conflict of interest.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
